(Q34333196)

1 August 2017

Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data (English)

1 reference

1 August 2017

1 reference

Anne T Nies

3

0 references

author name string

Gökce Orhan

1

1 reference

1 August 2017

Thomas V Wuttke

2

1 reference

1 August 2017

Matthias Schwab

4

1 reference

1 August 2017

Holger Lerche

5

1 reference

1 August 2017

language of work or name

English

0 references

publication date

12 July 2012

1 reference

Expert Opinion on Pharmacotherapy

1 August 2017

1 reference

1 August 2017

13

1 reference

1 August 2017

12

1 reference

1 August 2017

1807-1816

1 reference

The epidemiology of epilepsy revisited

1 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Management of epilepsy in adolescents and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Reduction of spike frequency adaptation and blockade of M‐current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Effects of retigabine on rhythmic synchronous activity of human neocortical slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Pathways modulating neural KCNQ/M (Kv7) potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Neuronal KCNQ potassium channels: physiology and role in disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Effects of age and sex on the disposition of retigabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

An introduction to antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Antiepileptic drug therapy: does mechanism of action matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.706278

10.1517/14656566.2012.706278

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference